# Patent

## Title
Truncated L1 protein of human papillomavirus type 6

## Abstract

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

## Background
CROSS REFERENCE TO RELATED APPLICATIONS
This is the U.S. National Phase of PCT/CN2008/001050, filed May 29, 2008, which in turn claims priority to Chinese Patent Application No. 200710105764.7, filed May 29, 2007, the contents of both of which are incorporated herein in their entirety by reference.
FIELD OF THE INVENTION
The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum and HPV (especially HPV6) infection.
BACKGROUND OF THE INVENTION
The human papillomavirus, a non-enveloped, deoxyribonucleic acid (DNA) virus, belongs to the genus of papovaviridae. The viral genome is a closed circle, double-stranded DNA, which is approximately 7.2-8 kb in length and contains 8 open reading frames (ORFs). The genome can be divided into three parts in terms of function: (1) the early region (E), approximately 4.5 Kb in length, coding for 6 non-structural proteins E1, E2, E4 ̃E7 associated with virus replication, transcription and transformation; (2) the late region (L), approximately 2.5 Kb in length, coding for the major capsid protein L1 and the minor capsid protein L2; (3) the long control region (LCR), located between the end of the L region and the initiating terminal of the E region, approximately 800-900 bp in length, and comprising regulator elements for DNA replication and expression instead of coding for proteins. Viral particles are 45-55 nm in diameter, wherein the nucleocapsid, consisting of L1 and L2, exhibits icosahedral symmetry and comprise 72 capsomers.
Currently, there are over 90 different types of HPV, mainly causing papillary disease in the skin and mucosa of human. HPV types are divided into three groups depending on their relation with tumorigenesis: (1) group of low or no cancerogenic risk, containing types 6, 11, 39, 41, 42, and 43; (2) group of medium cancerogenic risk, containing types 31, 33, 35, 51, and 52; and (3) group of high cancerogenic risk, containing types 16, 18, 45, and 56.
Epidemiological investigation reveals that HPV (such as HPV6, 11) infection in the anal-genital mucosa is the third most common sexually transmitted disease following trichomoniasis and chlamydia. Pathological changes caused by HPV types 6 and 11 account for about 90% of these cases. In America, HPV infection of genital meatus among women occurs most frequently when they are 15-25 years old and is highly related to the infected person's sexual behavior. In China, HPV infection among women occurs most frequently when they are 20-29 years old, and the infection rate is 1606.1/100,000. Women are less infected with HPV as they grow older than 35. However, since the majority of HPV infections are sub-clinical, it is difficult to accurately estimate the infection rate. As estimated by the US CDC, the risk is approximately 10% during the whole life. In addition, there is little data regarding HPV infection among men, due to the difficulty of sample collection and the lesser severity of consequences. Currently, HPV infection rate among men is believed to be close to the one among women. In the United States, condyloma acuminatum can be found in 1% of sexually active adult men. Therefore, the development of a safe, efficient vaccine for HPV 6 and 11 would be an effective way to prevent sexually transmitted diseases.
HPV L1 protein, with a molecular weight of 55-60 kDa, is the major capsid protein of the human papillomavirus and the main target protein of the HPV vaccine. HPV L1 protein expressed in multiple different expression systems can form Virus-like particles (VLPs) which resemble native HPV particles morphologically, without the assistance of the L2 protein. The VLP, consisting of 72 pentamers of the L1 proteins, exhibits icosahedral symmetry. Since the VLPs retain the native epitopes of the viral particles, they are highly immunogenic and can induce the generation of neutralizing antibodies against homologous HPV (Kirnbauer, R., F. Booy, et al. 1992 Proc Natl Acad Sci USA 89(24): 12180-4). Furthermore, the VLPs are safe and have no potential cancergenic risk as they contain no viral DNA. Therefore, VLP vaccines become the primary candidate for an HPV vaccine.
The key for development of a vaccine is to efficiently produce VLP vaccines of HPV in large-scale. Currently, the most commonly used expression systems are eukaryotic expression systems and prokaryotic expression systems.
The commonly used eukaryotic systems comprise poxvirus, insect baculovirus and yeast vectors. HPV L1 protein expressed in eukaryotic systems shows little conformational difference from that of the native virus, and can self-assemble into VLPs. Thus, purified VLPs can be easily obtained after gradient density centrifugation. It brings a lot of convenience to the purification work. However, due to the high culture costs and low expression level, it is quite difficult to product industrially on a large-scale. The HPV vaccine Gardasil®, which came into the market recently, is more expensive than others due to low expression level and high production cost of the Saccharomyces cerevisiae expression system employed in its manufacture.
The expression of HPV L1 protein in a prokaryotic system such as E. coli has been previously reported. Banks, Matlashewski, et al. published a paper regarding the expression of HPV 16 L1 by employing E. coli (Banks, L., G Matlashewski, et al. (1987). J Gen Virol 68 (Pt 12): 3081-9). However, most HPV L1 proteins expressed by E. coli lose their native conformation and cannot induce the generation of protective antibodies against HPV. Alternatively, although HPV VLPs can be obtained from the incorrectly folded proteins by steps such as purification from inclusion bodies and refolding, it is difficult to apply this method to large-scale production, as the protein is largely lost during the refolding process and the yield is low (Kelsall, S. R. and J. K. Kulski (1995). J Virol Methods 53(1): 75-90). Although HPV L1 protein may be expressed in a soluble form with a correct conformation in E. coli and dissolved in the supernatants of E. coli lysate, the expression level is low. Moreover, since there are large number and amount of impure proteins, it is difficult to isolate the proteins of interest from them. Although it is reported that the expression level of L1 protein can be increased in the supernatants by means of GST fusion expression and the purification of the protein of interest is facilitated (Li, M., T. P. Cripe, et al. (1997), J Virol 71(4): 2988-95), it still cannot be applied to large-scale production because expensive enzymes are required to cleave the fusion protein.
Therefore, a HPV L1 protein capable of inducing the generation of protective antibodies against HPV, and a virus-like particle consisting of the same are still needed in the art, so that it is possible to produce vaccines for condyloma acuminatum industrially on a large scale.
DESCRIPTION OF THE INVENTION
This invention aims to provide a novel HPV type 6 L1 protein, the virus-like particles (VLPs) consisting of it, and a vaccine comprising the VLPs.
During research, it was found by chance that the E. coli expression system can produce a truncated HPV 6 L1 protein that can induce the generation of neutralizing antibodies against HPV 6. After purification, the truncated HPV6 L1 protein can be produced in high yield, with at least 50% purity. Further treatment of the purified HPV L1 protein can produce VLPs, which can induce the production of neutralizing antibodies against HPV6. The invention has been completed based on the above.
Therefore, the first aspect of the invention relates to HPV 6 L1 proteins with 2, 3, 4, or 5 amino acids truncated at N-terminal as compared to a wild type HPV 6 L1 protein. Preferably, the truncated protein has the sequence set forth in SEQ ID Nos:1, 2, 3, or 4, especially the sequence set forth in SEQ ID NO:1.
A further aspect of the invention relates to a polynucleotide encoding the truncated protein according to the invention, and a vector containing the polynucleotide.
A further aspect of the invention relates to a cell comprising the vector.
The invention also relates to a composition comprising the truncated protein, the polynucleotide, the vector, or the cell.
A further aspect of the invention relates to a HPV 6 VLP, comprising or consisting of a HPV 6 L1 protein with 2, 3, 4, or 5 amino acids truncated at the N terminal such as a HPV 6 L1 protein having a sequence set forth in SEQ ID NOs: 1, 2, 3, or 4.
A further aspect of the invention relates to a method for obtaining the HPV 6 L1 protein, comprising the expression of a truncated HPV 6 L1 gene fragment in an E. coli system and the subsequent purification of the protein from the lysate supernatant.
In a preferred embodiment of the invention, a method for obtaining HPV 6 L1 protein comprises:

    
    
        a) expressing the truncated HPV 6 L1 gene fragment in a E. coli expression system;
        b) disrupting E. coli, which has expressed the truncated HPV 6 L1 protein, in a salt solution at a concentration of from 100 mM to 600 mM, and isolating the supernatant;
        c) decreasing the salt concentration of the supernatant in b) to from 100 mM to 0, inclusive, by using water or a low salt solution, and collecting a precipitate;
        d) redissolving the precipitation in c) in a salt solution at a concentration of from 150 mM to 2500 mM, with a reductant added, and then isolating the resultant solution, wherein the solution contains the truncated HPV 6 L1 protein with a purity of at least 50%.
    
    


More generally, the invention also relates to a method for obtaining a HPV L1 protein, such as the HPV 6 L1 protein according to the invention, comprising:

    
    
        a) expressing a HPV L1 gene encoding the HPV L1 protein in an E. coli expression system;
        b) disrupting E. coli, which has expressed the HPV L1 protein, in a salt solution at a concentration of from 100 mM to 600 mM, and isolating the supernatant;
        c) decreasing the salt concentration of the supernatant in b) to from 100 mM to 0, inclusive, by using water or a low salt solution, and collecting a precipitate;
        d) redissolving the precipitation of c) in a salt solution at a concentration of from 150 mM to 2500 mM, with a reductant added, and then isolating the resultant solution, wherein the solution contains the HPV L1 protein with a purity of at least 50%.
    
    


The invention also relates to a vaccine for the prevention of condyloma acuminatum or HPV infection, comprising VLPs of HPV 6 L1 proteins according to the invention. Preferably, the vaccine further comprises at least one VLPs selected from VLPs of HPV 18, 11, 16, 31, 33, 45, 52, and 58 L1 proteins. Generally, the vaccine further contains excipients or vectors for vaccine.
Preferably, the vaccine comprises HPV 6 VLPs and HPV 11 VLPs, especially the HPV 6 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 4, and the HPV 11 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 7. More preferably, the vaccine further comprises HPV 16 VLPs and HPV 18 VLPs, especially the HPV 16 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 8, and the HPV 18 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 9.
In a specially preferred embodiment, the vaccine comprises the HPV 6 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 4, the HPV 11 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 7, the HPV 16 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 8, and the HPV 18 VLPs comprising or consisting of a protein having an amino acid sequence set forth in SEQ ID No: 9.
The invention further relates to the use of the HPV 6 L1 protein or the VLPs thereof in the manufacture of a vaccine for the prevention of condyloma acuminatum or HPV infections.
The invention further relates to a method for preventing condyloma acuminatum or HPV infections, comprising administrating a vaccine comprising an preventively effective amount of HPV 6 L1 protein to a human or animal in need of preventing condyloma acuminatum or HPV infections.
The invention involves a method for obtaining VLPs of the HPV 6 L1 protein, comprising:

    
    
        e) further purifying the truncated HPV 6 L1 protein with a purity of at least 50% by subjecting it to a chromatography;
        f) removing the reductant from the HPV 6 L1 protein obtained in e).
    
    


This invention involves a method for preparing a vaccine for preventing condyloma acuminatum or HPV infections, comprising blending the VLPs above, and optionally, one or more VLPs selected from the group consisting of VLPs of HPV 11, 16, 18, 31, 33, 45, 52 and 58, with carriers or excipients useful for vaccines.
Definitions of the Term in Present Invention
According to the invention, the term “E. coli expression system” refers to a expression system consisting of E. coli (strains) and vectors, wherein the E. coli (strains) include, but are not limited to: GI698, ER2566, BL21 (DE3), B834 (DE3), and BLR (DE3), which are available on the market.
According to the invention, the term “vectors” refers to the nucleic acid carrier tools which can have a polynucleotide encoding a protein inserted therein and allow for the expression of the protein. The “vector” can have the carried genetic material expressed in a host cell by transformation, transduction, and transfection into the host cell. For example, “vectors” include plasmids, phages, cosmids and the like.
According to the invention, the term “a gene fragment of a truncated HPV 6 L1 protein” refers to the nucleic acids with the nucleotide(s) encoding one or more amino acid sequences deleted at 5′ or 3′ terminal of the wild-type HPV 6 L1 gene (cDNA). The full-length gene sequence of the wild-type HPV 6 L1 gene can be found in, but not limited to, the following NCBI sequences: AF067042.1, AF092932.1, L41216.1 and X00203.1.
The term “truncated HPV 6 L1 protein” refers to the protein with one or more amino acids deleted at the N- and/or C-terminal of the wild-type HPV 6 L1 protein. The full-length gene sequence of the wild-type HPV 6 L1 protein can be found in, but not limited to, the full-length L1 proteins encoded by the following NCBI sequences: AF067042.1, AF092932.1, L41216.1 and X00203.1.
According to the invention, the term “carriers and excipients useful for vaccines” refers to one or more reagents, including but not limited to: pH regulators, surfactants, adjuvants, and ionic strength enhancers. For example, pH regulators include, but are not limited to, phosphate buffers; surfactants include, but are not limited to: anion surfactants, cation surfactants, non-ionic surfactants (for example, but not limited to Tween-80); adjuvants include, but are not limited to, aluminum hydroxide and Freund's complete adjuvant; and Ionic strength enhancers include, but are not limited to, NaCl.
According to the invention, the term “chromatography” includes, but is not limited to: ion exchange chromatography (e.g. cation-exchange chromatography), hydrophobic interaction chromatography, absorbant chromatography (e.g. hydroxyapatite chromatography), gel filtrate chromatography (gel exclusion chromatography), and affinity chromatography.
According to the invention, the truncated HPV 6 L1 proteins may be obtained preferably by the following steps:

    
    
        a) disrupting E. coli, which expresses truncated HPV 6 L1 protein, in a buffer containing 100-600 mM salt, preferably 200-500 mM;
        b) isolating the supernatant from the disrupted solution, then decreasing the salt concentration of the supernatant to 100 mM-0 M with water or a low-salt buffer (generally, with a salt concentration lower than the one of the buffer for disrupting);
        c) separating a precipitant from the supernatant with a salt concentration as low as 100 mM-0;
        d) redissoving the precipitant in a solution containing a reductant and having a salt concentration of 150-2000 mM, preferably greater than 200 mM;
        e) isolating a solution of the truncated HPV 6 L1 proteins with a purity of at least 50%, preferably at least 70%, more preferably at least 80%.
    
    


According to the invention, in the method for obtaining the truncated HPV 6 L1 proteins, the term “buffer” refers to a solution which can maintain pH value stable within a certain range, including but not limited to: Tris buffers, phosphate buffers, HEPES buffers, and MOPS buffers.
According to the invention, the disrupting of the prokaryotic host cell can be achieved by methods including, but not limited to one or more of homogenizer disrupting, ultrasonic treatment, grinding, high pressure extrusion, and lysozyme treatment.
According to the invention, in the method for obtaining the truncated HPV 6 L1 proteins, the salts used include, but are not limited to: one or more of neutral salts, especially alkali metal salt, ammonium salts, hydrochlorides, sulfates, bicarbonates, phosphate salts or hydrogenphosphates, espeically NaCl, KCl, NH4Cl, (NH4)2SO4. NaCl are preferred. The reductant used includes, but is not limited to, DTT and 2-mercaptoethanol, in an amount of including, but not limited to, 10-100 mM.
According to the invention, the VLPs of the truncated HPV 6 L1 protein may be produced by the following steps: further purifying the truncated HPV 6 L1 protein with a purity of at least 50% by subjecting it to a chromatography, and thereby obtaining a purified truncated HPV 6 L1 protein solution; and removing the reductant from the purified HPV 6 L1 protein solution, and thereby obtaining VLPs of the truncated HPV 6 L1. Methods for removing the reductant include, but are not limited to, known techniques in the art, such as dialysis, ultrafiltration, and chromatography.
According to the invention, the truncated HPV L1 protein preferably has the sequence set forth in SEQ ID NO:1.
According to the invention, the vaccine may be administrated in a patient-acceptable form, including but not limited to oral and injection, preferably injection.
According to the invention, the vaccine is preferably used in a unit dose. Each unit dose contains 5-80 μg truncated HPV 6 L1 VLP, preferably 20-40 μg.
Beneficial Effect
Presently, the expression systems useful for preparing HPV VLPs include eukaryotic and prokaryotic expression systems.
HPV L1 proteins expressed in eukaryotic expression systems retain their native conformation, and can form VLPs on their own. In most cases, VLP with a correct conformation can be obtained by simple purification. Nevertheless, eukaryotic expression systems, such as the baculovirus and yeast expression systems, are difficult to be applied in large-scale industrial production due to low expression levels and high costs.
Prokaryotic expression systems, such as E. coli systems, have the advantages of high expression levels at a lower cost. However, when expressed in a prokaryotic system, the HPV L1 protein usually loses its native conformation and is expressed in a form of inclusion bodies in the precipitant. Renaturation of the protein from inclusion bodies is still a problem worldwide. Due to the difficulty and inefficiency of renaturation, this method is limited to small-scale lab research and cannot be applied on a large scale so as to obtain VLP with a correct conformation from the inclusive bodies. Although the HPV L1 protein can exist in its native conformation in the supernatant of E. coli lysate, its expression levels are low. Moreover, it is quite difficult to purify the HPV L1 protein from the numerous soluble proteins in the E. coli lysate supernatant. Generally, the purification is completed by means such as fusion expression and affinity chromatography which are not feasible for industrial-scale processes due to expensive enzymes employed therein.
In this invention, N-truncated HPV 6 L1 protein is expressed in an E. coli expression system and is selectively precipitated from the E. coli lysate supernatant under mild conditions. The HPV 6 L1 protein is then redissolved in a salt buffer to significantly improve its purity while still retaining its native conformation. The redissolved protein of interest can be immediately subjected to ion-exchange or hydrophobic interaction chromatography so as to obtain the pure protein. The purified, truncated HPV 6 L1 protein obtained from these steps, can self-assemble into VLPs with good immunogenicity and the ability to induce neutralizing antibodies of a high titer against HPV 6, which is a good vaccine for preventing human from HPV 6 infection. In addition, the truncated HPV 6 L1 protein used in the present invention, with the antigenicity and particle-selfassembly ability of the full-length HPV 6 L1 protein retained, is easily expressed in an E. coli expression system, and can be economically purified without using expensive enzymes. Furthermore, because the protein of interest is not subjected to the intensive procedures of denaturation and renaturation during purification, the method can be applied industrially on a large scale due to low loss.
The invention will be more apparent after referring to the detailed description and the drawings as follows. All public references are incorporated hereby by reference in their entirety.



DESCRIPTION OF DRAWINGS
FIG. 1 shows the SDS-PAGE result of HPV6N3C-L1 protein during steps a)-d) of the method according to the invention. Lane 1: Lysate supernatant; Lane 2: HPV6N3C-L1 protein precipitated by tengenital flow; Lane 3: Redissolved HPV6N3C-L1 in a re-suspension solution. The result shows that the purity of HPV6N3C-L1 reached about 70% following the steps of precipitation and re-dissolution.
FIG. 2 shows the SDS-PAGE result of HPV6N3C-L1 that was obtained in step d) and was further purified according to step e). Lane 1: HPV6N3C-L1 purified according to step e), 10 μL; Lane 2: HPV6N3C-L1 purified according to step e), 20 μL. The result shows that HPV6N3C-L1 purified according to step e) reached a purity of about 98%.
FIG. 3 shows the transmission electron microscopy (TEM) photograph of HPV6N3C-L1 VLPs obtained in step f), taken at 50,000× magnification. A great deal of VLPs in a radius of about 25 nm were observed in visual field, wherein the particle size was consistant with the theoretic size and the particles were homogenous.
FIG. 4 shows the dynamic light-scattering measurement result of HPV6N3C-L1 VLPs obtained in step f). The result shows that HPV6N3C-L1 VLP had a hydrodynamic radius of 24.70 nm and a particle assembly rate of 100%.
FIG. 5 shows titers of neutralizing antibodies in serum at different stages after vaccination of goat with HPV6N3C-L1 VLPs. Vaccination times are indicated with arrows. The titer of neutralizing antibodies increased rapidly a week after the first vaccination, and reached a peak level of 107-108 after a booster.
FIG. 6 shows titers of neutralizing antibodies in serum at different stages a week after vaccination of rabbit with HPV6N3C-L1 VLPs. Vaccination times are indicated with arrows. The titer of neutralizing antibodies increased rapidly a week after the first vaccination, and reached a peak level of 106 after a booster.
FIG. 7 shows the titers of neutralizing antibodies against HPV 6 and HPV11 in serum at different times after vaccination of mice with HPV6/11 bivalent vaccine obtained in Example 5. Vaccine was administered at 0 and 2 weeks. The titers of neutralizing antibodies against HPV6 and HPV 11 increased rapidly after the first vaccination, reaching 104-105.
FIG. 8 shows the titers of neutralizing antibodies against HPV 6, HPV 11, HPV 16 and HPV 18 in serum at different times after vaccination of mice with HPV6/11/16/18 quadrivalent vaccine obtained in Example 5. Vaccine was administered at 0 and 2 weeks. The titers of neutralizing antibodies against HPV 6, HPV 11, HPV 16 and HPV 18 increased rapidly after the first vaccination, reaching 105-106.
FIG. 9 shows the SDS-PAGE results of HPV6N2C-L1, HPV6N4C-L1 and HPV6N5C-L1 protein separately having 2, 4 and 5 amino acids truncated at the N-terminal of HPV 6 L1 protein (the amino acid sequences thereof set forth in SEQ ID Nos: 2, 3 and 4, respectively) during steps a)-e) of the method according to the invention. Lane 1: Molecular Weight Marker; Lane 2: HPV6N2C-L1 purified according to step a)-e), 10 μL; Lane 3: HPV6N4C-L1 purified according to step a)-e), 10 μL; Lane 4: HPV6N5C-L1 purified according to step a)-e), 10 μL. The result shows that the purity of HPV6N2C-L1, HPV6N4C-L1 and HPV6N5C-L1 protein separately having 2, 4 and 5 amino acids truncated at the N-terminal of HPV 6 L1 protein, reached about 98% following the steps a)-e).
FIG. 10 the transmission electron microscopy (TEM) photographs of the VLPs of HPV6N2C-L1, HPV6N4C-L1 and HPV6N5C-L1 protein separately having 2, 4 and 5 amino acids truncated at the N-terminal of HPV 6 L1 protein obtained after steps a)-f), taken at 50,000× magnification. 1. The transmission electron microscopy (TEM) photographs of HPV6N2C-L1 VLPs obtained after steps a)-f), taken at 50,000× magnification. 2 The transmission electron microscopy (TEM) photographs of HPV6N4C-L1 VLPs obtained after steps a)-f), taken at 50,000× magnification. 3. The transmission electron microscopy (TEM) photographs of HPV6N5C-L1 VLPs obtained after steps a)-f), taken at 50,000× magnification. The results show that a great deal of VLPs in a radius of about 25 nm were observed in visual field, wherein the particle size was consistant with the theoretic size and the particles were homogenous.
FIG. 11 shows the dynamic light-scattering measurement result of the VLPs of HPV6N2C-L1, HPV6N4C-L1 and HPV6N5C-L1 protein separately having 2, 4 and 5 acids truncated at the N-terminal of HPV 6 L1 protein obtained after steps a)-f). 1. The dynamic light-scattering measurement result of HPV6N2C-L1 VLPs obtained after steps a)-f). 2. The dynamic light-scattering measurement result of HPV6N4C-L1 VLPs obtained after steps a)-f). 3. The dynamic light-scattering measurement result of HPV6N5C-L1 VLPs obtained after steps a)-f). The result shows that HPV6N2C-L1 VLPs, HPV6N4C-L1 VLPs and HPV6N5C-L1 VLPs had a hydrodynamic radius of about 25 nm and a particle assembly rate of 100%.



SEQUENCES







SEQ ID NO: 1:








   1
MPSDSTVYVP PPNPVSKVVA TDAYVTRTNI FYHASSSRLL


 



AVGHPYFSIK RANKTVVPKV


 


  61
SGYQYRVFKV VLPDPNKFAL PDSSLFDPTT QRLVWACTGL


 



EVGRGQPLGV GVSGHPFLNK


 


 121
YDDVENSGSG GNPGQDNRVN VGMDYKQTQL CMVGCAPPLG


 



EHWGKGKQCT NTPVQAGDCP


 


 181
PLELITSVIQ DGDMVDTGFG AMNFADLQTN KSDVPIDICG


 



TTCKYPDYLQ MAADPYGDRL


 


 241
FFFLRKEQMF ARHFFNRAGE VGEPVPDTLI IKGSGNRTSV


 



GSSIYVNTPS GSLVSSEAQL


 


 301
FNKPYWLQKA QGHNNGICWG NQLFVTVVDT TRSTNMTLCA


 



SVTTSSTYTN SDYKEYMRHV


 


 361
EEYDLQFIFQ LCSITLSAEV VAYIHTMNPS VLEDWNFGLS


 



PPPNGTLEDT YRYVQSQAIT


 


 421
CQKPTPEKQK PDPYKNLSFW EVNLKEKFSS ELDQYPLGRK


 



FLLQSGYRGR SSIRTGVKRP


 


 481
AVSKASAAPK RKRAKTKR


 







SEQ ID NO: 2








   1
MRPSDSTVYV PPPNPVSKVV ATDAYVTRTN IFYHASSSRL


 



LAVGHPYFSI KRANKTVVPK


 


  61
VSGYQYRVFK VVLPDPNKFA LPDSSLFDPT TQRLVWACTG


 



LEVGRGQPLG VGVSGHPFLN


 


 121
KYDDVENSGS GGNPGQDNRV NVGMDYKQTQ LCMVGCAPPL


 



GEHWGKGKQC TNTPVQAGDC


 


 181
PPLELITSVI QDGDMVDTGF GAMNFADLQT NKSDVPIDIC


 



GTTCKYPDYL QMAADPYGDR


 


 241
LFFFLRKEQM FARHFFNRAG EVGEPVPDTL IIKGSGNRTS


 



VGSSIYVNTP SGSLVSSEAQ


 


 301
LFNKPYWLQK AQGHNNGICW GNQLFVTVVD TTRSTNMTLC


 



ASVTTSSTYT NSDYKEYMRH


 


 361
VEEYDLQFIF QLCSITLSAE VVAYIHTMNP SVLEDWNFGL


 



SPPPNGTLED TYRYVQSQAI


 


 421
TCQKPTPEKQ KPDPYKNLSF WEVNLKEKFS SELDQYPLGR


 



KFLLQSGYRG RSSIRTGVKR


 


 481
PAVSKASAAP KRKRAKTKR


 







SEQ ID NO: 3








   1
MSDSTVYVPP PNPVSKVVAT DAYVTRTNIF YHASSSRLLA


 



VGHPYFSIKR ANKTVVPKVS


 


  61
GYQYRVFKVV LPDPNKFALP DSSLFDPTTQ RLVWACTGLE


 



VGRGQPLGVG VSGHPFLNKY


 


 121
DDVENSGSGG NPGQDNRVNV GMDYKQTQLC MVGCAPPLGE


 



HWGKGKQCTN TPVQAGDCPP


 


 181
LELITSVIQD GDMVDTGFGA MNFADLQTNK SDVPIDICGT


 



TCKYPDYLQM AADPYGDRLF


 


 241
FFLRKEQMFA RHFFNRAGEV GEPVPDTLII KGSGNRTSVG


 



SSIYVNTPSG SLVSSEAQLF


 


 301
NKPYWLQKAQ GHNNGICWGN QLFVTVVDTT RSTNMTLCAS


 



VTTSSTYTNS DYKEYMRHVE


 


 361
EYDLQFIFQL CSITLSAEVV AYIHTMNPSV LEDWNFGLSP


 



PPNGTLEDTY RYVQSQAITC


 


 421
QKPTPEKQKP DPYKNLSFWE VNLKEKFSSE LDQYPLGRKF


 



LLQSGYRGRS SIRTGVKRPA


 


 481
VSKASAAPKR KRAKTKR


 







SEQ ID NO: 4








   1
MDSTVYVPPP NPVSKVVATD AYVTRTNIFY HASSSRLLAV


 



GHPYFSIKRA NKTVVPKVSG


 


  61
YQYRVFKVVL PDPNKFALPD SSLFDPTTQR LVWACTGLEV


 



GRGQPLGVGV SGHPFLNKYD


 


 121
DVENSGSGGN PGQDNRVNVG MDYKQTQLCM VGCAPPLGEH


 



WGKGKQCTNT PVQAGDCPPL


 


 181
ELITSVIQDG DMVDTGFGAM NFADLQTNKS DVPIDICGTT


 



CKYPDYLQMA ADPYGDRLFF


 


 241
FLRKEQMFAR HFFNRAGEVG EPVPDTLIIK GSGNRTSVGS


 



SIYVNTPSGS LVSSEAQLFN


 


 301
KPYWLQKAQG HNNGICWGNQ LFVTVVDTTR STNMTLCASV


 



TTSSTYTNSD YKEYMRHVEE


 


 361
YDLQFIFQLC SITLSAEVVA YIHTMNPSVL EDWNFGLSPP


 



PNGTLEDTYR YVQSQAITCQ


 


 421
KPTPEKQKPD PYKNLSFWEV NLKEKFSSEL DQYPLGRKFL


 



LQSGYRGRSS IRTGVKRPAV


 


 481
SKASAAPKRK RAKTKR


 







SEQ ID NO: 5








   1
ATGTGGCGGC CTAGCGACAG CACAGTATAT GTGCCTCCTC


 



CTAACCCTGT ATCCAAAGTT


 


  61
GTTGCCACGG ATGCTTATGT TACTCGCACC AACATATTTT


 



ATCATGCCAG CAGTTCTAGA


 


 121
CTTCTTGCAG TGGGTCATCC TTATTTTTCC ATAAAACGGG


 



CTAACAAAAC TGTTGTGCCA


 


 181
AAGGTGTCAG GATATCAATA CAGGGTATTT AAGGTGGTGT


 



TACCAGATCC TAACAAATTT


 


 241
GCATTGCCTG ACTCGTCTCT TTTTGATCCC ACAACACAAC


 



GTTTGGTATG GGCATGCACA


 


 301
GGCCTAGAGG TGGGCAGGGG ACAGCCATTA GGTGTGGGTG


 



TAAGTGGACA TCCTTTCCTA


 


 361
AATAAATATG ATGATGTTGA AAATTCAGGG AGTGGTGGTA


 



ACCCTGGACA GGATAACAGG


 


 421
GTTAATGTTG GTATGGATTA TAAACAAACA CAATTATGCA


 



TGGTTGGATG TGCCCCCCCT


 


 481
TTGGGCGAGC ATTGGGGTAA AGGTAAACAG TGTACTAATA


 



CACCTGTACA GGCTGGTGAC


 


 541
TGCCCGCCCT TAGAACTTAT TACCAGTGTT ATACAGGATG


 



GCGATATGGT TGACACAGGC


 


 601
TTTGGTGCTA TGAATTTTGC TGATTTGCAG ACCAATAAAT


 



CAGATGTTCC TATTGACATA


 


 661
TGTGGCACTA CATGTAAATA TCCAGATTAT TTACAAATGG


 



CTGCAGACCC ATATGGTGAT


 


 721
AGATTATTTT TTTTTCTACG GAAGGAACAA ATGTTTGCCA


 



GACATTTTTT TAACAGGGCT


 


 781
GGCGAGGTGG GGGAACCTGT GCCTGATACT CTTATAATTA


 



AGGGTAGTGG AAATCGAACG


 


 841
TCTGTAGGGA GTAGTATATA TGTTAACACC CCAAGCGGCT


 



CTTTGGTGTC CTCTGAGGCA


 


 901
CAATTGTTTA ATAAGCCATA TTGGCTACAA AAAGCCCAGG


 



GACATAACAA TGGTATTTGT


 


 961
TGGGGTAATC AACTGTTTGT TACTGTGGTA GATACCACAC


 



GCAGTACCAA CATGACATTA


 


1021
TGTGCATCCG TAACTACATC TTCCACATAC ACCAATTCTG


 



ATTATAAAGA GTACATGCGT


 


1081
CATGTGGAAG AGTATGATTT ACAATTTATT TTTCAATTAT


 



GTAGCATTAC ATTGTCTGCT


 


1141
GAAGTAATGG CCTATATTCA CACAATGAAT CCCTCTGTTT


 



TGGAAGACTG GAACTTTGGG


 


1201
TTATCGCCTC CCCCAAATGG TACATTAGAA GATACCTATA


 



GGTATGTGCA GTCACAGGCC


 


1261
ATTACCTGTC AAAAGCCCAC TCCTGAAAAG CAAAAGCCAG


 



ATCCCTATAA GAACCTTAGT


 


1321
TTTTGGGAGG TTAATTTAAA AGAAAAGTTT TCTAGTGAAT


 



TGGATCAGTA TCCTTTGGGA


 


1381
CGCAAGTTTT TGTTACAAAG TGGATATAGG GGACGGTCCT


 



CTATTCGTAC CGGTGTTAAG


 


1441
CGCCCTGCTG TTTCCAAAGC CTCTGCTGCC CCTAAACGTA


 



AGCGCGCCAA AACTAAAAGG


 


1501
TAA


 







SEQ ID NO: 6








   1
ATGCCTAGCG ACAGCACAGT ATATGTGCCT CCTCCTAACC


 



CTGTATCCAA


 


  51
AGTTGTTGCC ACGGATGCTT ATGTTACTCG CACCAACATA


 



TTTTATCATG


 


 101
CCAGCAGTTC TAGACTTCTT GCAGTGGGTC ATCCTTATTT


 



TTCCATAAAA


 


 151
CGGGCTAACA AAACTGTTGT GCCAAAGGTG TCAGGATATC


 



AATACAGGGT


 


 201
ATTTAAGGTG GTGTTACCAG ATCCTAACAA ATTTGCATTG


 



CCTGACTCGT


 


 251
CTCTTTTTGA TCCCACAACA CAACGTTTGG TATGGGCATG


 



CACAGGCCTA


 


 301
GAGGTGGGCA GGGGACAGCC ATTAGGTGTG GGTGTAAGTG


 



GACATCCTTT


 


 351
CCTAAATAAA TATGATGATG TTGAAAATTC AGGGAGTGGT


 



GGTAACCCTG


 


 401
GACAGGATAA CAGGGTTAAT GTTGGTATGG ATTATAAACA


 



AACACAATTA


 


 451
TGCATGGTTG GATGTGCCCC CCCTTTGGGC GAGCATTGGG


 



GTAAAGGTAA


 


 501
ACAGTGTACT AATACACCTG TACAGGCTGG TGACTGCCCG


 



CCCTTAGAAC


 


 551
TTATTACCAG TGTTATACAG GATGGCGATA TGGTTGACAC


 



AGGCTTTGGT


 


 601
GCTATGAATT TTGCTGATTT GCAGACCAAT AAATCAGATG


 



TTCCTATTGA


 


 651
TATATGTGGC ACTACATGTA AATATCCAGA TTATTTACAA


 



ATGGCTGCAG


 


 701
ACCCTTATGG TGATAGATTA TTTTTTTTTC TACGGAAGGA


 



ACAAATGTTT


 


 751
GCCAGACATT TTTTTAACAG GGCTGGCGAG GTGGGGGAAC


 



CTGTGCCTGA


 


 801
TACTCTTATA ATTAAGGGTA GTGGAAATCG AACGTCTGTA


 



GGGAGTAGTA


 


 851
TATATGTTAA CACCCCAAGC GGCTCTTTGG TGTCCTCTGA


 



GGCACAATTG


 


 901
TTTAATAAGC CATATTGGCT ACAAAAAGCC CAGGGACATA


 



ACAATGGTAT


 


 951
TTGTTGGGGT AATCAACTGT TTGTTACTGT GGTAGATACC


 



ACACGCAGTA


 


1001
CCAACATGAC ATTATGTGCA TCCGTAACTA CATCTTCCAC


 



ATACACCAAT


 


1051
TCTGATTATA AAGAGTACAT GCGTCATGTG GAAGAGTATG


 



ATTTACAATT


 


1101
TATTTTTCAA TTATGTAGCA TTACATTGTC TGCTGAAGTA


 



GTGGCCTATA


 


1151
TTCACACAAT GAATCCCTCT GTTTTGGAAG ACTGGAACTT


 



TGGGTTATCG


 


1201
CCTCCCCCAA ATGGTACATT AGAAGATACC TATAGGTATG


 



TGCAGTCACA


 


1251
GGCCATTACC TGTCAAAAGC CCACTCCTGA AAAGCAAAAG


 



CCAGATCCCT


 


1301
ATAAGAACCT TAGTTTTTGG GAGGTTAATT TAAAAGAAAA


 



GTTTTCTAGT


 


1351
GAATTGGATC AGTATCCTTT GGGACGCAAG TTTTTGTTAC


 



AAAGTGGATA


 


1401
TAGGGGACGG TCCTCTATTC GTACCGGTGT TAAGCGCCCT


 



GCTGTTTCCA


 


1451
AAGCCTCTGC TGCCCCTAAA CGTAAGCGCG CCAAAACTAA


 



AAGGTAA






The description is further illustrated in combination with the Examples, wherein it is not limited to the Examples.
Example 1
Expression of the Truncated HPV6 L1 Protein (SEQ ID NO.1)
Preparation of HPV6 L1 Gene Fragments as PCR Template
The full-length gene of HPV-6 L1 was synthesized by Shanghai Boya Bio Co. The synthesized gene fragment has a full length of 1503 bp and has a sequence of SEQ ID NO:5. Based on the synthetic full-length gene fragment of HPV-6 L1, the truncated HPV 6 L1 protein according to the invention was prepared as a template.
Construction of Non-Fusion Expression Vector of Truncated HPV6 L1 gene
The full-length gene fragment of HPV-6 L1 synthesized in the previous step were used as the template for the next PCR reaction. The forward primer was 6N3F: 5′-CAT ATG CCT AGC GAC AGC ACA GTA TA-3′ (SEQ ID NO:10), at the 5′ terminal of which the restriction endonuclease NdeI site was introduced. The sequence of NdeI site was CAT ATG, wherein ATG was the initiation codon in E. coli system. The reverse primer was 6CR: 5′-GTC GAC TTA CCT TTT AGT TTT GGC GC-3′ (SEQ ID NO:11), at the 5′ terminal of which the restriction endonuclease SalI site was introduced. Amplification was performed in a Biometra T3 PCR thermocycler using the following parameters:

















94° C. denaturation 5 min
1
cycle



94° C. denaturation 50 sec
25
cycles



57° C. annealing 50 sec



72° C. elongation 2 min



72° C. elongation 10 min
1
cycle










The DNA fragments, about 1.5 kb in length, were obtained after amplification. The PCR products were linked to the pMD 18-T vector (Takara Biosciences). After digestion with NdeI/SalI, it was identified that positive colonies, wherein the truncated HPV6 L1 gene was inserted, were obtained, designated as pMD 18-T-HPV6N3C-L1.
The nucleotide sequence of interest, which was inserted into the plasmid pMD 18-T-HPV6N3C-L1, was determined as SEQ ID NO: 6 by Shanghai Boya Bio Co. through using M13+/− primers. SEQ ID NO:6 encodes the amino acid sequence set forth in SEQ ID NO:1 which corresponds to a HPV 6 L1 protein having 3 amino acids truncated at its N-terminal and no amino acid truncated at its C-terminal and was designated as HPV6N3C-L1.
The truncated HPV6N3C-L1 gene fragments were obtained by NdeI/SalI digestion of plasmid pMD 18-T-HPV6N3C-L1. The fragments were linked to the prokaryotic expression vector pTrxFus digested with NdeI/SalI (Invitrogen). Since the fusion protein was cleaved, the protein of interest was expressed immediately after initiating the expression of the amino acid Met, without other fusion proteins included. Colonies were screened with NdeI/SalI digestion. Positive colonies containing the insert of the L1 gene fragment were labeled pTRX-HPV6N3C-L1. 1 μL plasmid pTRX-HPV6N3C-L1 (0.15 mg/ml) was used to transform 40 μL competent E. coli GI698 (Invitrogen) prepared by Calcium chloride method, and then were coated on solid CAA media (dissolving 6 g Na2HPO4, 3 g KH2PO4, 0.5 g NaCl, 1 g NH4Cl, 20 g casein hydrolysate, 0.095 MgCl2, 1.5 g agar powder, and 20 ml 50% glycerinin 900 ml deionized water, and was added) containing benzyl chloride (at a final concention of 100 mg/ml, the same as below). Plates were incubated at 30° C. for about 10-12 h until single colonies could be observed clearly. Single colonies from the plates were transferred to a tube containing 4 ml liquid IMC medium containing benzyl chloride. Cultures were incubated in a shaking incubator at 220 rpm for 10 h at 25° C., and then 1 ml bacterial solution was freeze-dried and stored at −70° C.
Expression of HPV6N3C-L1 in Large Scale
E. coli transformed with pTRX-HPV6N3C-L1 was taken from freeze-dried stain at −70° C., and diluted with a little sterile water, and then incubated in 50 mL IMC medium containing benzyl amine at 200 rpm and 30° C. for 8 h. Then, the cultures were transferred to ten flasks (5 ml cultures per flask), each of which contains 500 mL LB medium, and were incubated in a shaking incubator overnight at 200 rpm and 30° C.
A 50 L fermenter made by Shanghai Baoxing Biological Ltd was used in large-scale incubation. pH electrode was calibrated. 30 L LB medium was prepared and transferred into the fermenter, sterilized at 121° C. for 30 minutes. Dissolved oxygen electrode was calibrated, wherein the value was determined as 0 before introduction of air after sterilization and as 100% prior to vaccintation after introduction of air while stirring at 100 rpm at the beginning.
Preparation of the feed: 30 g casein hydrolysates was dissolved in 100 mL deionized water to prepare a solution (30%), and 50 g glucose was dissolved in 100 ml deionized water to prepared a glucose solution (50%). The two mixtures were sterilized at 121° C. for 20 min.
On the second day, the starter cultures in the ten flasks (for a total of 5 L) were transferred to the fermenter. At 30° C. and pH 7.0, the dissolved O2 was maintained at >40% by regulating agitation rate or air supply manually.
Flow Feed: 50% glucose and 30% casein hydrolysates were mixed at a 2:1 mass ratio.
Flow rates were as follows:
25 ml/min was defined as 100%.
1 h: 5%
2 h: 10%
3 h: 20%
4 h: 40%
5 h to the end: 60%
When OD600 reached about 10.0, the culture temperature was lowered to 25° C. and 4 g tryptophan was added to begin an induction culture of 4 h. Fermentation was halted when OD600 reached about 40. The culture was then centrifuged to obtain strains (about 2.5 kg).
IMC medium (1 liter):

















Na2HPO4
6
g



KH2PO4
3
g



NaCl
0.5
g



NH4Cl
1
g



Casein Hydrolysates
20
g



MgCl2
0.095
g










Example 2
Preparation of HPV6N3C-L1 with a Purity of about 70%
1 g strains were re-suspended in 10 ml lysis buffer (20 mM tris buffer pH 7.2, 300 mM NaCl). Strains were disrupted by passing through a APV homogenizer (Invensys Group) for five times at a pressure of 600 bar. The homogenate was centrifuged at 30,000 g (13,500 rpm in JA-14 rotor) for 15 min. The supernatant was subjected to SDS-PAGE on a 10% gel. At this stage, the HPV6N3C-L1 had a purity of about 10%. The supernatant was dialyzed by a Centrasette 5 Tangential Flow Filter (Pall Co.) running at a pressure of 0.5 psi, a flow rate of 500 ml/min, and a tangential flow rate of 200 mL/min, wherein the retention molecular weight was 30 kDa, the dialysate was 10 mM phosphate buffer pH 6.0, and the dialysis volume was three times as large as the volume of supernatant. After thorough dialysis, the mixture was centrifuged at 12,000 g (9500 rpm in JA-10 rotor (Beckman J25 high speed centrifuge)) for 20 min, and the precipitation was collected. The precipitation was re-suspended in 10 mM phosphate buffer pH 7.0 containing 10 mM DTT and 300 mM NaCl, wherein the volume of the buffer was 1/10 times as large as the volume of the supernatant. The mixture was stirred for 30 min and centrifuged at 30,000 g (13,500 rpm in JA-14 rotor (Beckman J25 high speed centrifuge)) for 20 min. The supernatant passes through a 0.22 μm filter membrane. The sample was further subjected to cation exchange chromatography. 300 μL of 6× loading buffer was added to 150 μL of the filtered supernatant, and the result solution was mixed. After heating in a water bath at 80° C. for 10 min, 10 ul of the sample was subjected to SDS-PAGE on a 10% gel at 120V for 120 min. The electrophoretic bands were stained by Coomassie brilliant blue. The result was shown in FIG. 1. According to the analysis of SDS-PAGE, HPV6N3C-L1 protein was purified and enriched after the steps of precipitation and re-dissolution, with the purity of about 70%.
Example 3
Chromatography Purification of HPV6N3C-L1
Purification of HPV6N3C-L1 by Cation exchange Chromatography
Equipment: AKTA Explorer 100 preparative liquid chromatography system (GE Healthcare, i.e. the original Amershan Pharmacia Co.)
Chromatographic media: SP Sepharose 4 Fast Flow
Column Volume: 5.5 cm×20 cm
Buffer: 20 mM phosphate buffer pH 7.0, 10 mM DTT

    
    
        20 mM phosphate buffer pH 7.0, 10 mM DTT, 2M NaCl
    
    


Flow Rate: 25 mL/min
Detector Wavelength: 280 nm
Sample: 3 L 70% pure HPV6N3C-L1 solution
Elution protocol: eluting undesired proteins with 200 mM NaCl, eluting the protein of interest with 500 mM NaCl, collecting 500 mM NaCl elutate, and finally getting about 900 mL purified HPV6N3C-L1 sample.
Purification of HPV6N3C-L1 by CHT-II Chromatography
Equipment: AKTA Explorer 100 preparative liquid chromatography system (GE Healthcare, i.e. the original Amershan Pharmacia Co.)
Chromatographic media: CHT-II (Bio-Rad)
Column Volume: 5.5 cm×20 cm
Buffer: 10 mM phosphate buffer pH7.0, 10 mM DTT, 0.5M NaCl
Flow Rate: 20 mL/min
Detector Wavelength: 280 nm
Sample: 500 mM NaCl elutate from SP Sepharose 4 Fast Flow
Elution protocol: directly collecting the pass-through containing the protein of interest.
The pass-through, which contains HPV6N3C-L1, was collected and about 1000 mL purified HPV6N3C-L1 was obtained. 30 μL 6× loading buffer was added to 150 μL HPV6N3C-L1 sample purified according to the method of the Example, and then the result solution was mixed thoroughly. After heating the solution in a water bath at 80° C. for 10 min, a 10 uL sample was subjected to SDS-PAGE on a 10% gel at 120V for 120 min. The electrophoretic bands were stained by Coomassie brilliant blue. The result was shown in FIG. 2. The concentration of the protein of interest was about 0.7 mg/ml, and the purity was greater than 98% according to SDS-PAGE.
Example 4
Assembly of HPV6N3C-L1 VLPs
Equipment: Centrasette 5 Tangential Flow Filter (Pall Co.), retention MW 30 kDa.
Sample: 1000 mL HPV6N3C-L1 obtained in Example 3
Sample Concentration: Sample was concentrated to 800 mL with the system tangential flow rate was adjusted to 50 mL/min
Sample renaturation: Sample Renaturation: Sample buffer was exchanged with 10 L renaturation buffer (20 mM PB pH 6.0, 2 mM CaCl2, 2 mM MgCl2, 0.5M NaCl, 0.003% Tween-80) thoroughly. When running the Tangential Flow Filter, the pressure was 0.5 psi and the tangential flow rate was 10 mL/min. When exchange was finished, the sample buffer was replaced with storage buffer (20 L PBS: 20 mM PB pH 6.5, 0.5M NaCl). The exchange volume was 20 L. The running pressure was 0.5 psi and the tangential flow rate was 25 mL/min. When the liquid exchange was finished, the sample was aseptically filtrated with a Pall filter (0.20 μm), and thereby obtaining HPV6N3C-L1 VLPs. The HPV6N3C-L1 VLPs were stored at 4° C. for further use.
Example 5
Determination of the Morphology and Immunogenicity of HPV6N3C-L1 VLPs
Transmission Electron Microscopy (TEM) of HPV6N3C-L1 VLPs
The equipment was a JEOL 100 kV Transmission Electron Microscope (100,000× magnification). HPV6N3C-L1 VLPs were negatively stained with 2% phosphotungstic acid at pH 7.0, and fixed on a copper grid. Results were shown in FIG. 3. It could be seen that the VLPs obtained in Example 4 had a radius of approximately 25 nm, and were homogenous and in a hollow form.
Dynamic Light-Scattering Measurement of HPV6N3C-L1 VLPs
DynaPro MS/X dynamic light-scattering instrument (including a temperature controller) (US Protein Solutions Co.) was used for light-scattering measurements. The regulation algorithm was used in the measurements. The sample was the one obtained in Example 4. The sample was passed through a 0.22 μm filter membrane prior to the measurement. Results were shown in FIG. 4. The result shows that HPV6N3C-L1 VLPs had a Hydrodynamic radius of 25.46 nm.
Establishment a Model of Pseudovirion Neutralization Assay for HPV6:
HPV can hardly be cultured in vitro, and the HPV host had a strong specificity. Thus, HPV can hardly be propagated in hosts other than human. That is, there was not an appropriate animal model for HPV. Therefore, in order to evaluate the immune productivity of HPV vaccine quickly, there was a need to establish a efficient model for in vitro neutralization assays.
In Vitro Infection Model of Pseudovirion: According to the characteristic that HPV VLP can package nucleic acids non-specifically, HPV pseudivirion was formed by expressing HPV L1 and L2 protein in cells, and by packaging viral DNA of episome or introducing reporter plasmids heterologously. Methods include expression systems based on recombinant viruses and cotransfection of multi-plasmids (see Yeager, M. D, Aste-Amezaga, M. et al (2000) Virology (278) 570-7).
The invention utilizes cotransfection of a multi-plasmid system. Some improvements were made as follows. An optimized calcium phosphate transfection method was established for the 293FT cell line, with a transfection efficiency of above 90%, which facilitate the production on a large scale. The resultant codon-optimized expression plasmid of HPV protein could express HPV L1 and L2 gene efficiently in mammalian cell lines, facilitating efficient assembly of pseudovirion.
1. Construction of HPV Pseudovirion:
P6L1h, p6L2h and pN31-EGFP (donated by Professor John T. Schiller of NIH) contain genes for HPV6L1, HPV6L2, and GFP, respectively. These plasmids were purified using CsCl density gradient centrifugation as described in The Molecular Cloning Experiment Guide, (3rd edition). The purification procedure was as follows:

    
    
        Plasmids were used to transform E. coli DH5α;
        Single colonies were transferred into 500 mL LB culture medium and incubated in a shaking flask at 37° C. for 16 h;
        Culture medium was centrifuged at 9,000 g for 5 min and the stains were collected;
        The following substances were successively added to bacteria in each 1000 mL LB: 40 mL solution I (50 mM glucose, 25 mM Tris-Cl pH 8.0, 10 mM EDTA pH 8.0) and 2 ml μg/μL RNase A), 40 mL solution II (0.2M NaOH, 1% SDS), and 48 mL solution III (60.0 mL 5M potassium acetate, 11.5 mL acetic acid, and 28.5 mL deionized water);
        After placing on ice for 10 min, the mixture was centrifuged at 15,000 g for 20 min at 4° C.;
        The supernatant was mixed with 0.6 volume of isopropyl alcohol, then was centrifuged again at 15,000 g for 30 min;
        The supernatant was decanted into waste and the precipitation was washed with 70% ethanol;
        The precipiation was dissolved in TE and the content of DNA was determined;
        CsCl was dissolved in the solution of DNA (1 g DNA per 1.01 g CsCl), and then 100 μL 10 mg/mL EB solution was also dissolved in it;
        The mixture was centrifuged using a Beckman NVT65 centrifuge at 62,000 rpm for 10 hr at 20° C.;
        Closed circle DNA section was collected using an injector pinhead;
        EB was extracted with equivalent volume of Isoamyl alcohol repeatedly for four times;
        Three volumes of deionized water and eight volumes of dry ethanol were added to one volume of DNA solution, and then the mixture was centrifuged at 20000 g for 30 min at 4° C.;
        The precipitation was collected and washed with 75% ethanol, and then dissolved in 1 mL TE;
        The concentration of the DNA solution was determined, then the solution was stored in small packages at −20° C.
    
    


The purified p6L1h, p6L2h and pN31-EGFP co-transfected 293FT cells (Invitrogen) cultured on a 10 cm cell culture plate by calcium phosphate method. The calcium phosphate method was described as follows. 40 μg p6L1h, 40 μg p6L2h and 40 μg pN31-EGFP were separately added to the mixture of 1 mL HEPES solution (125 μL 1M HEPES/50 mL deionized water, at pH7.3 and 4° C.) and 1 mL 0.5M CaCl2 solution. After mixing, 2 mL 2× HeBS solution (0.28M NaCl (16.36 g), 0.05M HEPES (11.9 g), 1.5 mM Na2HPO4 (0.213 g), dissolved in 1000 mL deionized water, at pH 6.96 and −70° C.) was added dropwise. After standing at room temperature for 1 min, the mixture was added to the 10 cm cell culture plate where the 293FT cells were cultured. The original culture medium was replaced with 10 ml complete medium (Invitrogen Co.) 6 hours later. 48 hours after transfection, the medium was decanted and the cells were washed twice with PBS. Then, the cells were collected and counted. Every 108 cells were suspended in 1 mL cytolytic solution (0.25% Brij58, 9.5 mM MgCl2). After lysing, cell lysate was centrifugated at 5,000 g for 10 min and the supernatant was collected. The Pseudovirion solution was obtained after adding 5M NaCl to the supernatant to a final concentration of 850 mM, then was stored in small packages at −20° C.
293FT cells (Invitrogen) were spread on a 96-well cell culture plate (1.5×104 cells/well). Neutralization assay was performed five hours later. Serum samples were serially diluted with 10% DMEM half-by-half 50 μL diluted samples were separately mixed with 50 μL Pseudovirion solutions diluted with 10% DMEM (moi=0.1). After incubating at 4° C. for 1 h, the mixture was added to the 96-well cell culture plate spread with 293FT cells. The mixture was then incubated for 72 h at 37° C. Neutralization titers of samples were estimated by observing fluorescence. Infection percentage of cells in each well was checked by flow cytometry (EPICS XL, American Beckman Coulter Co.). The exact titers of monoclonal antibodies or polyclonal antibodies were calculated. Infection percentage was the percentage of cells in the positive region minus the uninfected cells in the positive region.

Infection control percentage=(1−infection percentage of sample cell/infection percentage of negative cell)×100%

Neutralization titer was defined as the highest dilution multiple by which the infection control percentage was just above 50%. Monoclonal and polyclonal antibodies were considered as having neutralizing capacity if their infection control percentage was above 50% after 50 times dilutions.
Measurement of Immune Protection of Animals Vaccinated with HPV6 VLPs
Female rabbits (general level), 6-8 weeks old, were purchased from the Disease Prevention and Control Center of Guangxi province, where they were raised. HPV6N3C-L1 VLPs prepared in Example 4, were mixed with equal amount of complete Freund's Adjuvant for the first immunization. For the booster, HPV6N3C-L1 VLPs were mixed with incomplete Freund's Adjuvant. Rabbits were immunized via muscle injection, with 100 μg per rabbit for the first immunization, and with 50 μg per rabbit for the booster separately at week 4, 10. After immunization, external vein blood was collected every week, and serum was separated and stored for detection.
Female goats (general level), 6-8 weeks old, were purchased from the Disease Prevention and Control Center of Guangxi province, where they were raised. HPV6N3C-L1 VLPs as prepared in Example 4, were mixed with equal amount of complete Freund's adjuvant for the first immunization. For the booster, HPV6N3C-L1 VLPs were mixed with incomplete Freund's adjuvant. Goats were immunized via muscle injection, with 1 mg per goat for the first immunization, and with 0.5 mg per goat for the booster separately at weeks 4, 10 and 18. After immunization, external vein blood was collected, and serum was separated and stored for detection.
Neutralization titers of the anti-serums were evaluated using a pseudovirion-based neutralization cell model assay. As shown in FIGS. 5 and 6, the vaccine produced by mixing HPV6N3C-L1 VLPs prepared in Example 4 with Freund's adjuvants (aluminum hydroxide or aluminum phosphate adjuvants available commercially or self-prepared may be used besides Freund's adjuvants) had good immunogenicity, could induce neutralizing antibodies with a high titer in animals, and could be used as an effective vaccine for the prevention of HPV infection.
Measurement of Immune Protection of Mice Vaccinated with HPV6/11 Bivalent Vaccine.
Four SPF BALB/c mice, 4-5 weeks old, were used. HPV6N5C-L1 and HPV11N4C-L1 VLPs, prepared according to the method similar to that of Examples 1-4, were mixed at a ratio of 1:2 (by weight), wherein the final concentrations of them were 40 μg/mL and 80 μg/mL, respectively. The vaccine was mixed with an equal amount of complete Freund's adjuvant for the first immunization, and was mixed with an equal amount of incomplete Freund's adjuvant for the booster.
Mice were immunized by muscle injection. The amount for the first immunization was 10 μg HPV6N5C-L1 and 20 μg HPV11N4C-L1 per mouse. The booster was administered every two weeks. The amount for the booster was 20 μg HPV6N5C-L1 and 40 μg HPV11N4C-L1 per mouse.
After immunization, external vein blood was collected every week and serum was separated. The titers of neutralizing antibodies against HPV6 and HPV11 in immunized mice were separately determined according to the method of Example 5.
Results were shown in FIG. 7, indicating that HPV6/11 bivalent vaccine, prepared by blending HPV6N5C-L1 and HPV11N4C-L1 VLPs as prepared in Examples 1-4, had good immunogenicity, could induce neutralizing antibodies with a high titer against HPV 6 and HPV 11 in animals, and could be used as an effective vaccine for the prevention of HPV6/HPV11 infection (besides the Freund's adjuvants used in the experiments, the vaccine may be prepared by blending the two HPV6N5C-L1 and HPV11N4C-L1, with aluminum hydroxide or aluminum phosphate adjuvants available commercially or self-prepared).
The Amino Acid Sequence of HPV11N4C-L1 is showed in SEQ ID NO: 7 as follows.








Met Ser Asp Ser Thr Val Tyr Val Pro Pro Pro Asn Pro Val Ser Lys



1                 5                      10                    15


 


Val Val Ala Thr Asp Ala Tyr Val Lys Arg Thr Asn Ile Phe Tyr His


              20                     25                     30


 


Ala Ser Ser Ser Arg Leu Leu Ala Val Gly His Pro Tyr Tyr Ser Ile


         35                     40                     45


 


Lys Lys Val Asn Lys Thr Val Val Pro Lys Val Ser Gly Tyr Gln Tyr


    50                     55                      60


 


Arg Val Phe Lys Val Val Leu Pro Asp Pro Asn Lys Phe Ala Leu Pro


65                     70                    75                  80


 


Asp Ser Ser Leu Phe Asp Pro Thr Thr Gln Arg Leu Val Trp Ala Cys


                 85                     90                    95


 


Thr Gly Leu Glu Val Gly Arg Gly Gln Pro Leu Gly Val Gly Val Ser


            100                    105                   110


 


Gly His Pro Leu Leu Asn Lys Tyr Asp Asp Val Glu Asn Ser Gly Gly


        115                    120                   125


 


Tyr Gly Gly Asn Pro Gly Gln Asp Asn Arg Val Asn Val Gly Met Asp


    130                   135                   140


 


Tyr Lys Gln Thr Gln Leu Cys Met Val Gly Cys Ala Pro Pro Leu Gly


145                   150                   155                  160


 


Glu His Trp Gly Lys Gly Thr Gln Cys Ser Asn Thr Ser Val Gln Asn


                  165                   170                   175


 


Gly Asp Cys Pro Pro Leu Glu Leu Ile Thr Ser Val Ile Gln Asp Gly


            180                     185                    190


 


Asp Met Val Asp Thr Gly Phe Gly Ala Met Asn Phe Ala Asp Leu Gln


        195                   200                   205


 


Thr Asn Lys Ser Asp Val Pro Leu Asp Ile Cys Gly Thr Val Cys Lys


    210                    215                   220


 


Tyr Pro Asp Tyr Leu Gln Met Ala Ala Asp Pro Tyr Gly Asp Arg Leu


225                   230                   235                  240


 


Phe Phe Tyr Leu Arg Lys Glu Gln Met Phe Ala Arg His Phe Phe Asn


                 245                   250                   255


 


Arg Ala Gly Thr Val Gly Glu Pro Val Pro Asp Asp Leu Leu Val Lys


             260                    265                  270


 


Gly Gly Asn Asn Arg Ser Ser Val Ala Ser Ser Ile Tyr Val His Thr


         275                    280                     285


 


Pro Ser Gly Ser Leu Val Ser Ser Glu Ala Gln Leu Phe Asn Lys Pro


    290                     295                  300


 


Tyr Trp Leu Gln Lys Ala Gln Gly His Asn Asn Gly Ile Cys Trp Gly


305                   310                   315                  320


 


Asn His Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser Thr Asn Met


                 325                     330                  335


 


Thr Leu Cys Ala Ser Val Ser Lys Ser Ala Thr Tyr Thr Asn Ser Asp


            340                     345                    350


 


Tyr Lys Glu Tyr Met Arg His Val Glu Glu Phe Asp Leu Gln Phe Ile


         355                   360                  365


 


Phe Gln Leu Cys Ser Ile Thr Leu Ser Ala Glu Val Met Ala Tyr Ile


    370                    375                   380


 


His Thr Met Asn Pro Ser Val Leu Glu Asp Trp Asn Phe Gly Leu Ser


385                   390                   395                  400


 


Pro Pro Pro Asn Gly Thr Leu Glu Asp Thr Tyr Arg Tyr Val Gln Ser


                 405                   410                   415


 


Gln Ala Ile Thr Cys Gln Lys Pro Thr Pro Glu Lys Glu Lys Gln Asp


              420                   425                   430


 


Pro Tyr Lys Asp Met Ser Phe Trp Glu Val Asn Leu Lys Glu Lys Phe


         435                  440                   445


 


Ser Ser Glu Leu Asp Gln Phe Pro Leu Gly Arg Lys Phe Leu Leu Gln


    450                   455                   460


 


Ser Gly Tyr Arg Gly Arg Thr Ser Ala Arg Thr Gly Ile Lys Arg Pro


465                   470                   475                  480


 


Ala Val Ser Lys Pro Ser Thr Ala Pro Lys Arg Lys Arg Thr Lys Thr


                  485                    490                  495


 


Lys Lys






Measurement of Immune Protection of Mice Vaccinated with HPV6/11/16/18 Quadrivalent Vaccine
Four SPF BALB/c mice, 4-5 weeks old, were used. HPV6N5C-L1, HPV11N4C-L1, HPV16N30C-L1 and HPV18N65C-L1 VLPs, prepared according to the method similar to that of Examples 1-4, were mixed at a ratio of 1:2:2:1 (by weight), wherein the final concentrations of them were 40 μg/mL, 80 μg/mL, 80 μg/mL and 40 μg/mL, respectively. The vaccine was mixed with an equal amount of complete Freund's adjuvant for the first immunization, and was mixed with an equal amount of incomplete Freund's adjuvant for the booster.
Mice were immunized by muscle injection. The amount for the first immunization was 10 μg HPV6N5C-L1, 10 μg HPV18N65C-L1, 20 μg HPV11N4C-L1, and 20 μg HPV16N30C-L1 per mouse. The booster was administered every two weeks. The amount for the booster was 20 μg HPV6N5C-L1, 20 μg HPV18N65C-L1, 40 μg HPV11N4C-L1, and 40 μg HPV16N30C-L1 per mouse.
After immunization, external vein blood was collected every week and serum was separated. The titers of neutralizing antibodies against HPV6, HPV11, HPV16 and HPV18 in immunized mice were separately determined according to the method of Example 5.
Results were shown in FIG. 8, indicating that HPV6/11/16/18 quadrivalent vaccine, prepared by blending HPV6N5C-L1, HPV11N4C-L1, HPV16N30C-L1 and HPV18N65C-L1 VLPs as prepared in Examples 1-4, had good immunogenicity, could induce neutralizing antibodies with a high titer against HPV 6, HPV 11, HPV 16, and HPV 18 in animals, and could be used as a effective vaccine for the prevention of HPV6/HPV11/HPV16/HPV18 infection (in addition to the Freund's adjuvants used in the experiments, the vaccine could be prepared by blending the four HPV6N5C-L1, HPV11N4C-L1, HPV16N30C-L1 and HPV18N65C-L1 VLPs with aluminum hydroxide or aluminum phosphate adjuvants available commercially or self-prepared).
The Amino Acid Sequence of L1 of HPV6N5C-L1 is showed in SEQ ID NO 4 as follows.
The Amino Acid Sequence of L1 of HPV16N30C-L1 is showed in SEQ ID NO 8 as follows.








Met Leu Pro Ser Glu Ala Thr Val Tyr Leu Pro Pro Val Pro Val Ser



1                5                      10                     15


 


Lys Val Val Ser Thr Asp Glu Tyr Val Ala Arg Thr Asn Ile Tyr Tyr


              20                     25                     30


 


His Ala Gly Thr Ser Arg Leu Leu Ala Val Gly His Pro Tyr Phe Pro


         35                    40                     45


 


Ile Lys Lys Pro Asn Asn Asn Lys Ile Leu Val Pro Lys Val Ser Gly


     50                     55                     60


 


Leu Gln Tyr Arg Val Phe Arg Ile His Leu Pro Asp Pro Asn Lys Phe


65                    70                    75                   80


 


Gly Phe Pro Asp Thr Ser Phe Tyr Asn Pro Asp Thr Gln Arg Leu Val


                 85                     90                   95


 


Trp Ala Cys Val Gly Val Glu Val Gly Arg Gly Gln Pro Leu Gly Val


             100                    105                   110


 


Gly Ile Ser Gly His Pro Leu Leu Asn Lys Leu Asp Asp Thr Glu Asn


          115                   120                  125


 


Ala Ser Ala Tyr Ala Ala Asn Ala Gly Val Asp Asn Arg Glu Cys Ile


    130                     135                   140


 


Ser Met Asp Tyr Lys Gln Thr Gln Leu Cys Leu Ile Gly Cys Lys Pro


145                   150                  155                   160


 


Pro Ile Gly Glu His Trp Gly Lys Gly Ser Pro Cys Thr Asn Val Ala


                  165                    170                   175


 


Val Asn Pro Gly Asp Cys Pro Pro Leu Glu Leu Ile Asn Thr Val Ile


             180                   185                   190


 


Gln Asp Gly Asp Met Val Asp Thr Gly Phe Gly Ala Met Asp Phe Thr


        195                   200                   205


 


Thr Leu Gln Ala Asn Lys Ser Glu Val Pro Leu Asp Ile Cys Thr Ser


    210                   215                   220


 


Ile Cys Lys Tyr Pro Asp Tyr Ile Lys Met Val Ser Glu Pro Tyr Gly


225                   230                     235                240


 


Asp Ser Leu Phe Phe Tyr Leu Arg Arg Glu Gln Met Phe Val Arg His


                 245                  250                   255


 


Leu Phe Asn Arg Ala Gly Ala Val Gly Asp Asn Val Pro Asp Asp Leu


            260                     265                  270


 


Tyr Ile Lys Gly Ser Gly Ser Thr Ala Asn Leu Ala Ser Ser Asn Tyr


         275                    280                    285


 


Phe Pro Thr Pro Ser Gly Ser Met Val Thr Ser Asp Ala Gln Ile Phe


    290                    295                   300


 


Asn Lys Pro Tyr Trp Leu Gln Arg Ala Gln Gly His Asn Asn Gly Ile


305                  310                    315                  320


 


Cys Trp Gly Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser


                325                    330                   335


 


Thr Asn Met Ser Leu Cys Ala Ala Ile Ser Thr Ser Glu Thr Thr Tyr


            340                     345                   350


 


Lys Asn Thr Asn Phe Lys Glu Tyr Leu Arg His Gly Glu Glu Tyr Asp


        355                   360                   365


 


Leu Gln Phe Ile Phe Gln Leu Cys Lys Ile Thr Leu Thr Ala Asp Ile


    370                   375                   380


 


Met Thr Tyr Ile His Ser Met Asn Ser Thr Ile Leu Glu Asp Trp Asn


385                    390                   395                 400


 


Phe Gly Leu Gln Pro Pro Pro Gly Gly Thr Leu Glu Asp Thr Tyr Arg


                 405                   410                  415


 


Phe Val Thr Ser Gln Ala Ile Ala Cys Gln Lys His Thr Pro Pro Ala


             420                    425                    430


 


Pro Lys Glu Asp Pro Leu Lys Lys Tyr Thr Phe Trp Glu Val Asn Leu


        435                   440                     445


 


Lys Glu Lys Phe Ser Ala Asp Leu Asp Gln Phe Pro Leu Gly Arg Lys


    450                    455                  460


 


Phe Leu Leu Gln Ala Gly Leu Glu Ala Lys Pro Lys Phe Thr Leu Gly


465                  470                    475                  480


 


Lys Arg Lys Ala Thr Pro Thr Thr Ser Ser Thr Ser Thr Thr Ala Lys


                 485                    490                   495


 


Arg Lys Lys Arg Lys Leu


             500






The Amino Acid Sequence of L1 of HPV18N65C-L1 is showed in SEQ ID NO 9 as follows.








Met Arg Pro Ser Asp Asn Thr Val Tyr Leu Pro Pro Pro Ser Val Ala



1                5                     10                     15


 


Arg Val Val Asn Thr Asp Asp Tyr Val Thr Arg Thr Ser Ile Phe Tyr


             20                     25                    30


 


His Ala Gly Ser Ser Arg Leu Leu Thr Val Gly Asn Pro Tyr Phe Arg


         35                    40                    45


 


Val Pro Ala Gly Gly Gly Asn Lys Gln Asp Ile Pro Lys Val Ser Ala


     50                    55                    60


 


Tyr Gln Tyr Arg Val Phe Arg Val Gln Leu Pro Asp Pro Asn Lys Phe


65                    70                     75                  80


 


Gly Leu Pro Asp Thr Ser Ile Tyr Asn Pro Glu Thr Gln Arg Leu Val


                 85                     90                    95


 


Trp Ala Cys Ala Gly Val Glu Ile Gly Arg Gly Gln Pro Leu Gly Val


             100                    105                   110


 


Gly Leu Ser Gly His Pro Phe Tyr Asn Lys Leu Asp Asp Thr Glu Ser


        115                    120                  125


 


Ser His Ala Ala Thr Ser Asn Val Ser Glu Asp Val Arg Asp Asn Val


    130                    135                    140


 


Ser Val Asp Tyr Lys Gln Thr Gln Leu Cys Ile Leu Gly Cys Ala Pro


145                   150                   155                  160


 


Ala Ile Gly Glu His Trp Ala Lys Gly Thr Ala Cys Lys Ser Arg Pro


                   165                   170                   175


 


Leu Ser Gln Gly Asp Cys Pro Pro Leu Glu Leu Lys Asn Thr Val Leu


            180                   185                   190


 


Glu Asp Gly Asp Met Val Asp Thr Gly Tyr Gly Ala Met Asp Phe Ser


        195                   200                   205


 


Thr Leu Gln Asp Thr Lys Cys Glu Val Pro Leu Asp Ile Cys Gln Ser


    210                  215                    220


 


Ile Cys Lys Tyr Pro Asp Tyr Leu Gln Met Ser Ala Asp Pro Tyr Gly


225                    230                   235                 240


 


Asp Ser Met Phe Phe Cys Leu Arg Arg Glu Gln Leu Phe Ala Arg His


                 245                  250                   255


 


Phe Trp Asn Arg Ala Gly Thr Met Gly Asp Thr Val Pro Gln Ser Leu


            260                    265                  270


 


Tyr Ile Lys Gly Thr Gly Met Arg Ala Ser Pro Gly Ser Cys Val Tyr


         275                   280                    285


 


Ser Pro Ser Pro Ser Gly Ser Ile Val Thr Ser Asp Ser Gln Leu Phe


    290                     295                    300


 


Asn Lys Pro Tyr Trp Leu His Lys Ala Gln Gly His Asn Asn Gly Val


305                  310                    315                  320


 


Cys Trp His Asn Gln Leu Phe Val Thr Val Val Asp Thr Thr Arg Ser


                 325                    330                  335


 


Thr Asn Leu Thr Ile Cys Ala Ser Thr Gln Ser Pro Val Pro Gly Gln


            340                    345                    350


 


Tyr Asp Ala Thr Lys Phe Lys Gln Tyr Ser Arg His Val Glu Glu Tyr


        355                   360                     365


 


Asp Leu Gln Phe Ile Phe Gln Leu Cys Thr Ile Thr Leu Thr Ala Asp


    370                   375                   380


 


Val Met Ser Tyr Ile His Ser Met Asn Ser Ser Ile Leu Glu Asp Trp


385                     390                   395                400


 


Asn Phe Gly Val Pro Pro Pro Pro Thr Thr Ser Leu Val Asp Thr Tyr


                 405                    410                   415


 


Arg Phe Val Gln Ser Val Ala Ile Ala Cys Gln Lys Asp Ala Ala Pro


            420                      425                    430


 


Ala Glu Asn Lys Asp Pro Tyr Asp Lys Leu Lys Phe Trp Asn Val Asp


        435                    440                  445


 


Leu Lys Glu Lys Phe Ser Leu Asp Leu Asp Gln Tyr Pro Leu Gly Arg


    450                   455                   460


 


Lys Phe Leu Val Gln Ala Gly Leu Arg Arg Lys Pro Thr Ile Gly Pro


465                   470                   475                  480


 


Arg Lys Arg Ser Ala Pro Ser Ala Thr Thr Ala Ser Lys Pro Ala Lys


                 485                    490                   495


 


Arg Val Arg Val Arg Ala Arg Lys


            500






The Amino Acid Sequence of HPV11N4C-L1 VLP is shown in SEQ ID NO:7, as described above.
Example 6
The truncated HPV6L1 proteins set forth in SEQ ID NOs: 2, 3 and 4 were prepared according to the techniques used in examples 1-5. All these truncated proteins could be purified to an extent of above 98% and could be assembled into VLPs with a radius of about 25 nm. The results are shown in FIGS. 9, 10 and 11.

## Claims

1. A truncated recombinant human papillomavirus type 6 (HPV6) L1 protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3 and 4.

2. A recombinant polynucleotide encoding the protein according to claim 1.

3. A recombinant vector comprising the polynucleotide according to claim 2.

4. An isolated cell comprising the recombinant vector according to claim 3.

5. A composition comprising the protein according to claim 1.

6. A human recombinant papillomavirus type 6 (HPV6) virus-like particle (VLP) comprising the protein according to claim 1.

7. An immunogenic composition comprising:
(1) human papillomavirus type 6 (HPV6) virus-like particles (VLP) comprising a truncated recombinant human papillomavirus type 6 (HPV6) L1 protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 4,
(2) optionally, at least one HPV VLPs selected from the group consisting of VLPs of HPV type 11, 16, 18, 31, 33, 45, 52, and 58, and
(3) carriers or excipients.

8. An immunogenic composition comprising the recombinant protein of claim 1, and a carrier or excipient.

9. A method for inducing an immune response to HPV6 in an individual, comprising administering the composition according to claim 8 to an individual.

10. A method for inducing an immune response to HPV6 in an individual, comprising administering a composition comprising the HPV6 virus-like particle (VLP) according to claim 6 with carriers or excipients, and optionally, administering one or more VLPs selected from the group consisting of VLPs of HPV types 11, 16, 18, 31, 33, 45, 52, and 58.

11. A method for inducing an immune response to HPV6 in an individual, comprising administering the immunogenic composition according to claim 7 to an individual.

12. The immunogenic composition of claim 7, comprising human papillomavirus type 6 (HPV6) VLP and human papillomavirus type 11 (HPV11) virus-like particles (VLP), wherein the HPV6 VLP comprises the protein of SEQ ID NO:4, and wherein the HPV11 VLP comprises the protein of SEQ ID NO:7.

13. A method for inducing an immune response to HPV6 and HPV11 in an individual, comprising administering the immunogenic composition of claim 12 to an individual.

14. The immunogenic composition of claim 7, comprising human papillomavirus type 6 (HPV6) virus-like particle (VLP) comprising the protein of SEQ ID NO:4, a human papillomavirus type 11 (HPV11) VLP comprising the protein of SEQ ID NO:7, a human papillomavirus type 16 (HPV16) VLP comprising the protein of SEQ ID NO:8, and a human papillomavirus type 18 (HPV18) VLP comprising the protein of SEQ ID NO:9.